FDA Grants Fast-Track Voucher for Kids' Growth Disorder Drug
Published Date: 4/1/2026
Notice
Summary
The FDA just gave Ascendis Pharma a special priority review voucher for their new rare pediatric disease drug, YUVIWEL, which helps kids with achondroplasia grow taller. This voucher speeds up future drug reviews and can be a valuable asset, saving time and potentially money. Approved on February 27, 2026, this move highlights the FDA’s commitment to fast-tracking treatments for rare childhood conditions.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA approves YUVIWEL for children
You may have a new treatment option if your child has achondroplasia. YUVIWEL (navepegritide) was approved on February 27, 2026, and is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.
Priority review voucher issued to sponsor
The FDA issued a Rare Pediatric Disease Priority Review Voucher to Ascendis Pharma for YUVIWEL. The award is made under section 529 of the FD&C Act and the agency published notice of the award.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-06315 — Notice of Proposed Reinstatement of BLM New Mexico Terminated Oil and Gas Lease: NMNM141519
Enrique A. Cantu asked to bring back his New Mexico oil and gas lease NMNM141519, which was ended before. The Bureau of Land Management agrees to reinstate it starting January 1, 2022, with updated rental fees of $20 per acre and a 20% royalty. This means Cantu can keep drilling under new terms, and the lease stays active for the rest of its original time.
Next: 2026-06317 — Proposed Collection: 30-Day Comment Request; NCI Genomic Data Commons (GDC) Data Submission Request Form (National Cancer Institute)
The National Cancer Institute (NCI) wants your thoughts on a form used to submit cancer genetic data to their Genomic Data Commons. If you work with cancer research data, this is your chance to comment before May 1, 2026. There’s no cost to you, but your feedback helps keep data collection smooth and useful for science!